Noble Financial Has Bearish Estimate for GYRE Q1 Earnings

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Equities research analysts at Noble Financial dropped their Q1 2026 earnings per share (EPS) estimates for Gyre Therapeutics in a research note issued on Monday, November 10th. Noble Financial analyst R. Leboyer now expects that the company will earn $0.09 per share for the quarter, down from their previous estimate of $0.12. Noble Financial also issued estimates for Gyre Therapeutics’ Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.43 EPS.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $26.77 million during the quarter, compared to the consensus estimate of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

GYRE has been the subject of several other reports. Jefferies Financial Group started coverage on shares of Gyre Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $16.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Wednesday, October 8th. Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 16th. Finally, HC Wainwright assumed coverage on Gyre Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $18.00 target price for the company. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Trading Up 9.8%

Shares of GYRE opened at $7.92 on Tuesday. The firm has a fifty day moving average price of $7.72 and a 200-day moving average price of $8.12. The firm has a market capitalization of $762.80 million, a P/E ratio of 792.79 and a beta of 1.88. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $19.00.

Institutional Trading of Gyre Therapeutics

A number of institutional investors have recently modified their holdings of GYRE. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after purchasing an additional 1,996 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Gyre Therapeutics by 18.7% during the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock worth $127,000 after buying an additional 2,596 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Gyre Therapeutics by 22.1% in the first quarter. SBI Securities Co. Ltd. now owns 123,629 shares of the company’s stock valued at $954,000 after buying an additional 22,390 shares during the last quarter. American Century Companies Inc. acquired a new stake in Gyre Therapeutics in the first quarter worth about $184,000. Finally, Advantage Alpha Capital Partners LP grew its stake in shares of Gyre Therapeutics by 54.0% during the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after acquiring an additional 4,790 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.